We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Christopher Kane MD, FACS

Christopher J. Kane MD, FACS

Dean of Clinical Affairs, CEO of UC San Diego Health Physician Group, Professor of Urology, San Diego, California

Dr. Kane is on the Executive Governing Board of UC San Diego Health Sciences and the Executive Committee of UCSD’s Clinical Integration Network. Dr. Kane is an internationally recognized expert in prostate cancer and kidney cancer epidemiology, risk stratification and outcomes after treatment. Dr. Kane completed his urology residency at Oakland Naval Hospital and UC San Francisco. He earned his medical degree at Uniformed Services University and his BS degree in mechanical engineering at UC Davis. From 2009 to 2016 he was Co-Chair of the Renal Cell Carcinoma Advisory Task Force, National Cancer Institute. He is on the AUA guidelines in prostate cancer committee. He was elected to American Association of GU Surgeons in 2014. In 2017 he was elected to the Clinical Society of Genitourinary Surgeons. He was selected as a “Top Doctor” in San Diego in 2008-2019 and was selected as one of two Physician Healthcare Champions for 2010 in San Diego by the San Diego Business Journal. He was awarded the Distinguished Engineering Alumni Medal by UC Davis in 2011. He is a retired Navy Captain and a decorated veteran of Desert Storm. Dr. Kane has authored more than 370 publications and book chapters, primarily on prostate cancer risk factors and outcomes, prostate cancer surgery, and minimally invasive surgery for prostate and kidney cancer.


No disclosures reported.